Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.33 |
| ▸ | BMP1 | P13497 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22504456 | 0.82 | TDP1 (0.44) | TDP1ALDH1A1MAPTATMHPGD | |
| SCHEMBL11932289 | 0.82 | DPP8 (0.47) | DPP8DPP9TDP1ALDH1A1MAPT | |
| SCHEMBL11927996 | 0.82 | DPP8 (0.47) | DPP8DPP9TDP1ALDH1A1MAPT | |
| SCHEMBL19034979 | 0.78 | DPP8 (0.42) | DPP8DPP9TDP1ALDH1A1MAPT | |
| SCHEMBL19034978 | 0.78 | DPP8 (0.44) | DPP8DPP9TDP1ALDH1A1MAPT | |
| SCHEMBL6913164 | 0.73 | TGM2 (0.54) | DPP8DPP9ALDH1A1MAPTTGM2 | |
| SCHEMBL2454828 | 0.71 | HTR2A (0.45) | TDP1ALDH1A1MAPTATMHPGD | |
| SCHEMBL6943478 | 0.69 | DPP8 (0.61) | DPP8DPP9TDP1ALDH1A1MAPT | |
| SCHEMBL10500161 | 0.69 | DPP8 (0.58) | DPP8DPP9ALDH1A1MAPTTGM2 | |
| SCHEMBL11043244 | 0.69 | ALDH1A1 (0.45) | DPP8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11117915-B2 | Antibacterial aminoglycoside analogs | Cipla USA, Inc. (US) | 2021-09-14 | — | — | US | disclosed |
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | Cipla USA, Inc. | 2020-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317709-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, MRPL9, NQO2 | DPP8 277/4885DPP9 64/4885TDP1 2209/4885 |
| US-11117915-B2 | Antibacterial aminoglycoside analogs | MRPL21, MRPL9, NQO2 | DPP8 277/4885DPP9 64/4885TDP1 2209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.